Medtronic (MDT) Granted FDA Approval for Innovative Clinician Programmer for the Medtronic SynchroMed II Intrathecal Drug Delivery System for Chronic Pain and Severe Spasticity
Tweet Send to a Friend
Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of a new clinician programmer for use ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
